130 related articles for article (PubMed ID: 30843136)
1. Modeling Pancreatic Cancer Dynamics with Immunotherapy.
Hu X; Ke G; Jang SR
Bull Math Biol; 2019 Jun; 81(6):1885-1915. PubMed ID: 30843136
[TBL] [Abstract][Full Text] [Related]
2. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
[TBL] [Abstract][Full Text] [Related]
3. A mathematical prognosis model for pancreatic cancer patients receiving immunotherapy.
Li X; Xu JX
J Theor Biol; 2016 Oct; 406():42-51. PubMed ID: 27338302
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells.
Wang L; Wen W; Yuan J; Helfand B; Li Y; Shi C; Tian F; Zheng J; Wang F; Chen L; Liang L; Zhou L; Lee C; Chen Z; Guo Y; Wang H; Zhang Q; Qin W
Clin Cancer Res; 2010 Jan; 16(1):164-73. PubMed ID: 20028741
[TBL] [Abstract][Full Text] [Related]
5. Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8+ T cells combined with a DC vaccine.
Lutz-Nicoladoni C; Wallner S; Stoitzner P; Pircher M; Gruber T; Wolf AM; Gastl G; Penninger JM; Baier G; Wolf D
Immunol Cell Biol; 2012 Jan; 90(1):130-4. PubMed ID: 21383769
[TBL] [Abstract][Full Text] [Related]
6. A mathematical model for pancreatic cancer growth and treatments.
Louzoun Y; Xue C; Lesinski GB; Friedman A
J Theor Biol; 2014 Jun; 351():74-82. PubMed ID: 24594371
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer.
Ellermeier J; Wei J; Duewell P; Hoves S; Stieg MR; Adunka T; Noerenberg D; Anders HJ; Mayr D; Poeck H; Hartmann G; Endres S; Schnurr M
Cancer Res; 2013 Mar; 73(6):1709-20. PubMed ID: 23338611
[TBL] [Abstract][Full Text] [Related]
8. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
[TBL] [Abstract][Full Text] [Related]
9. An Antibody Designed to Improve Adoptive NK-Cell Therapy Inhibits Pancreatic Cancer Progression in a Murine Model.
Lee J; Kang TH; Yoo W; Choi H; Jo S; Kong K; Lee SR; Kim SU; Kim JS; Cho D; Kim J; Kim JY; Kwon ES; Kim S
Cancer Immunol Res; 2019 Feb; 7(2):219-229. PubMed ID: 30514792
[TBL] [Abstract][Full Text] [Related]
10. Republication: A Prospective Observational Study of Adoptive Immunotherapy for Cancer Using Zoledronate-Activated Killer (ZAK) Cells - An Analysis for Patients With Incurable Pancreatic Cancer.
Yamaguchi Y; Katata Y; Okawaki M; Sawaki A; Yamamura M
Anticancer Res; 2022 Feb; 42(2):1181-1187. PubMed ID: 35093924
[TBL] [Abstract][Full Text] [Related]
11. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment.
Lin M; Liang S; Wang X; Liang Y; Zhang M; Chen J; Niu L; Xu K
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2607-2618. PubMed ID: 28871458
[TBL] [Abstract][Full Text] [Related]
12. Mathematical Modelling for the Role of CD4
Makhlouf AM; El-Shennawy L; Elkaranshawy HA
Comput Math Methods Med; 2020; 2020():7187602. PubMed ID: 32148558
[TBL] [Abstract][Full Text] [Related]
13. Ordinary Differential Equation Models for Adoptive Immunotherapy.
Talkington A; Dantoin C; Durrett R
Bull Math Biol; 2018 May; 80(5):1059-1083. PubMed ID: 28382423
[TBL] [Abstract][Full Text] [Related]
14. Blocking transforming growth factor-β signaling pathway augments antitumor effect of adoptive NK-92 cell therapy.
Yang B; Liu H; Shi W; Wang Z; Sun S; Zhang G; Hu Y; Liu T; Jiao S
Int Immunopharmacol; 2013 Oct; 17(2):198-204. PubMed ID: 23806302
[TBL] [Abstract][Full Text] [Related]
15. Whole blood interferon-γ levels predict the therapeutic effects of adoptive T-cell therapy in patients with advanced pancreatic cancer.
Ishikawa T; Kokura S; Sakamoto N; Okayama T; Endo M; Tsuchiya R; Okajima M; Matsuyama T; Adachi S; Kamada K; Katada K; Uchiyama K; Handa O; Takagi T; Yagi N; Ando T; Uno K; Naito Y; Yoshikawa T
Int J Cancer; 2013 Sep; 133(5):1119-25. PubMed ID: 23420507
[TBL] [Abstract][Full Text] [Related]
16. 4-1BB Agonist Focuses CD8
Sakellariou-Thompson D; Forget MA; Creasy C; Bernard V; Zhao L; Kim YU; Hurd MW; Uraoka N; Parra ER; Kang Y; Bristow CA; Rodriguez-Canales J; Fleming JB; Varadhachary G; Javle M; Overman MJ; Alvarez HA; Heffernan TP; Zhang J; Hwu P; Maitra A; Haymaker C; Bernatchez C
Clin Cancer Res; 2017 Dec; 23(23):7263-7275. PubMed ID: 28947567
[No Abstract] [Full Text] [Related]
17. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells.
Schnurr M; Scholz C; Rothenfusser S; Galambos P; Dauer M; Röbe J; Endres S; Eigler A
Cancer Res; 2002 Apr; 62(8):2347-52. PubMed ID: 11956095
[TBL] [Abstract][Full Text] [Related]
18. Killing the "BAD": Challenges for immunotherapy in pancreatic cancer.
Li TJ; Wang WQ; Yu XJ; Liu L
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188384. PubMed ID: 32531324
[TBL] [Abstract][Full Text] [Related]
19. Adoptive cell transfer therapy for malignant gliomas.
Ishikawa E; Takano S; Ohno T; Tsuboi K
Adv Exp Med Biol; 2012; 746():109-20. PubMed ID: 22639163
[TBL] [Abstract][Full Text] [Related]
20. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
Front Immunol; 2018; 9():1955. PubMed ID: 30214445
[No Abstract] [Full Text] [Related]
[Next] [New Search]
